Sponsor study identifier
interventional
50
1 country
1
Study Start
October 31, 2022
Actual (reported)Primary Completion
April 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
July 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Multisite protocol to provide IV Ribavirin treatment to patients with probable or suspected case of Hemorrhagic Fever with Renal Syndrome (HFRS)
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 21, 2020
Actual (reported)February 25, 2020
Actual (reported)October 31, 2022
Actual (reported)April 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
July 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Reduction in Mortality with IV Ribavirin at 10days
Measuring the treatment effectiveness of the injected IV Ribavirin by the reduction of mortality and reported serious adverse events at the 10 days interval.
10 Days (+/-1)
Reduction in Mortality with IV Ribavirin at 14days
Measuring the treatment effectiveness of the injected IV Ribavirin by the reduction of mortality and reported serious adverse events at the 14 days interval.
14 Days (+/-2)
Reduction in Mortality with IV Ribavirin at 28-60days
Measuring the treatment effectiveness of the injected IV Ribavirin by the reduction of mortality and reported serious adverse events at the 28-60 days interval.
28-60 Days
Reported Adverse Events
0-60 days
The proposed clinical dose is based on drug dosage used in the HFRS clinical trial in China that demonstrated efficacy: Loading dose, 33 mg/kg (maximum dose: 2.64 g), followed by a dose of 16 mg/kg (maximum dose: 1.28 g) every 6 hours for the first 4 days (15 doses), and 8 mg/kg (maximum dose: 0.64 g) every 8 hours for the subsequent 3 days (9 doses).
Virazole (Ribavirin), USP Injection 0.1 g/mL in a phosphate buffer solution. Each vial contains 1.2 g of Ribavirin in 12 mL
Landstuhl Regional Medical Center
Landstuhl, Germany
First Submitted
February 21, 2020
First Posted
February 25, 2020
Study Start
October 31, 2022
Actual (reported)Primary Completion
High Dose Ribavirin in the Treatment of Chronic Hepatitis C
Contact the study team to confirm eligibility.
April 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
July 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
July 7, 2026
Record last verified: 2026-07
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: